Back

Survival analysis of tafamidis use in patients with ATTR cardiac amyloidosis

26 August 2023 (17:15 - 17:45)
Organised by: Logo
Congress Presentation Part of: Heart failure red flags and their management Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Neasa Starr

Mid-Western Regional Hospital, Co. Limerick (Ireland)

5 More presentations in this session

Presentation thumbnail
Evaluation of disease progression in patients with ATTR amyloidosis with cardiomyopathy following treatment with patisiran: post-hoc analysis of the APOLLO-B study
Professor T. Damy (Creteil, FR)
Abstract Slides Video
Presentation thumbnail
Acoramidis produces near-complete TTR stabilization in blood samples from patients with variant transthyretin amyloidosis that is greater than that achieved with tafamidis
Mr A. Ji (San Francisco, US)
Abstract Slides Video
Presentation thumbnail
The use of 99mTc-PYP SPECT/CT in monitoring therapeutic changes of eplontersen in patients with hereditary transthyretin cardiomyopathy
Doctor A. Yu (Hsinchu, TW)
Abstract Slides Video
Presentation thumbnail
The role of infliximab in treating refractory cardiac sarcoidosis
Doctor R. Ahmed (Newcastle-Upon-Tyne, GB)
Abstract Slides Video
Presentation thumbnail
Non-adherence to prescribed medications in ambulatory patients with heart failure assessed using liquid chromatography tandem mass spectrometry
Doctor S. Sze (Leicester, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure red flags and their management

The Event

Event poster

ESC Congress 2023

26 August 2023 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Survival in a contemporary, real-world, matched cohort of patients with transthyretin amyloid cardiomyopathy treated vs not treated with tafamidis
thumbnail
Congress Presentation
Impact of Tafamidis on survival in elderly patients in a real-world setting: insights from the Healthcare European Amyloidosis Registry
thumbnail
Congress Presentation
Tafamidis to treat patients with transthyretin cardiac amyloidosis (ATTR-CM): real-world data from a tertiary centre

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources